|
0
|
|
IL-17A-producing gammadelta T cells control pulmonary Mycobacterium abscessus infection in mice.
(nature.com)
|
Hu X
…
Lin Y
Nature Microbiology
2026-09-03
|
#infection
#immunity
#mycobacterium
#cytotoxicity
#immunotherapy
|
|
0
|
|
Syncytium-forming HSV-1 in cancer gene therapy: From molecular mechanisms to clinical translation.
(tandfonline.com)
|
Zhao X
…
Shen Y
Virulence
2026-09-03
|
#cancer
#oncolytic
#immunotherapy
#virotherapy
#virology
|
|
0
|
|
XAB06, a glyco-humanized broad-spectrum anti-Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model.
(journals.asm.org)
|
Royer P-J
…
Bassissi F
Antimicrobial Agents and Chemotherapy
2026-09-03
|
#antibody
#immunotherapy
#sepsis
#amr
#virulence
|
|
0
|
|
Membrane engagement by the HLA-A cytoplasmic tail regulates endocytosis and surface retention.
(linkinghub.elsevier.com)
|
Xu X
…
Zhao L
Cell Reports
2026-09-03
|
#endocytosis
#immunotherapy
#mhc
#trafficking
#cancer
|
|
0
|
|
ACLY palmitoylation reprograms macrophages histone acetylation rewiring to repress hepatocellular carcinoma.
(linkinghub.elsevier.com)
|
Zhao J
…
Qin H
Cell Reports
2026-09-03
|
#immunotherapy
#macrophage
#hepatocellular carcinoma
#metabolism
#epigenetics
|
|
0
|
|
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species.
(science.org)
|
Wesolowski AJ
…
Roychoudhuri R
Science
2026-09-03
|
#immunosuppression
#cancer
#immunity
#redox
#immunotherapy
|
|
0
|
|
Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy.
(linkinghub.elsevier.com)
|
Feng Q
…
Chen B
Cell Reports Medicine
2026-09-03
|
#cancer
#immunotherapy
#t cell
#engineered bacteria
#immunostimulation
|
|
0
|
|
BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.
(nature.com)
|
Wiche Salinas TR
…
Paiardini M
Nature Microbiology
2026-09-03
|
#hiv
#reservoir
#apoptosis
#immunotherapy
|
|
0
|
|
Extracellular vesicle proteins monitor and interfere with CLDN18.2-targeted CAR-T cell and antibody therapies against gastrointestinal cancers.
(nature.com)
|
Qi C
…
Zhang C
Nature Communications
2026-09-03
|
#immunotherapy
#biomarker
#extracellular vesicles
#car t cells
#gastrointestinal-cancer
|
|
0
|
|
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306).
(nature.com)
|
Yoon HH
…
Xu J
Nature Communications
2026-09-03
|
#cancer
#clinical trial
#immunotherapy
#chemotherapy
#esophageal
|